Y-Type Discrete PEG Derivative for Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polyethylene glycol (PEG) modifications for drugs face issues due to PEG's non-uniform molecular weight distribution, leading to insufficient water solubility enhancement of poorly soluble drugs, and the limitations of linear discrete polyethylene glycol derivatives in improving drug loading and solubility.
Innovation Solution
A Y-type discrete polyethylene glycol derivative with a branched structure and specific reactive sites is developed, allowing for increased drug loading and improved water solubility, featuring a structure with defined molecular weight and enhanced reactivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If linear discrete polyethylene glycol is used to modify drugs, then product uniformity is improved, but drug loading capacity and water solubility enhancement are insufficient
Solution Approach 1:
The patent divides the linear discrete polyethylene glycol structure into a branched Y-type structure with multiple arms. Each arm can independently bind to drug molecules, effectively increasing the drug loading capacity while maintaining product uniformity through controlled synthesis of discrete molecular weight variants.
Solution Approach 2:
The patent transitions from a one-dimensional linear structure to a three-dimensional branched structure. This dimensional change increases the spatial arrangement of reactive sites, allowing multiple drug molecules to be loaded simultaneously on different arms of the Y-type structure, thereby enhancing both drug loading capacity and water solubility.
2Quantity of substance
If PEG modification is applied to improve water solubility, then solubility enhancement is achieved, but product homogeneity deteriorates due to PEG's molecular weight distribution
Solution Approach 1:
The patent changes the molecular weight parameter of the polyethylene glycol component by using discrete PEG variants with defined molecular weights (e.g., PEG200, PEG400, PEG600, PEG800, PEG1000) rather than conventional PEG with broad molecular weight distributions. This parameter control ensures product homogeneity while maintaining water solubility enhancement.
Solution Approach 2:
The patent creates a composite structure combining discrete polyethylene glycol variants with defined molecular weights and specific core compounds. This composite approach allows control over both the homogeneity (through discrete PEG selection) and water solubility (through PEG's hydrophilic properties) of the modified drug product.
Data Source
AI summary
The present invention relates to a Y-type discrete polyethylene glycol derivative as shown by Formula (I). The Y-type discrete polyethylene glycol derivative has the advantages of a determined molecular weight and number of segments in the chain, and can avoid the defects where the polyethylene glycol derivative itself is a mixture and the molecular weight is not homogeneous. The Y-type polyethylene glycol of the present invention can solve the problem of insufficient water solubility caused by an increase in the loading capacity when the discrete polyethylene glycol modifies an insoluble drug while increasing the drug loading capacity.